Hepatobiliary surgery and nutrition · 2024
Prevalence and longitudinal effects on mortality associated with spectrum of alcohol intake in steatotic liver disease: a United States population study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ong Christen, Tang Nicole, Gunalan Shyna, Teng Margaret, Koh Benjamin, Chee Douglas, Koh Jia Hong, Tung Daniel, Syn Nicholas, Nakano Dan, Kulkarni Anand, Law Michelle, Miwa Takao, Takahashi Hirokazu, Muthiah Mark, Wijarnpreecha Karn, Ioannou George, Ng Cheng Han, Huang Daniel Q, Noureddin Mazen
Аннотация
BACKGROUND: The recently introduced set of terminologies defining categories of steatotic liver disease (SLD) includes metabolic dysfunction-associated SLD (MASLD), alcohol-associated liver disease (ALD), and metabolic dysfunction associated steatotic liver disease and increased alcohol intake (MetALD). The present retrospective cohort study examines clinical characteristics, prevalence, and mortality risk across alcoholic intake spectrum in SLD individuals.
METHODS: Data between 1999 to 2018 were extracted from National Health and Nutrition Examination Survey registries and analysed. Population baseline characteristics were evaluated across classifications of SLD. SLD was confirmed using either fatty liver index (FLI) or United States FLI (US-FLI). Multivariate analyses were used to study mortality-related outcomes.
RESULTS: The 20,510 individuals with SLD included were classified into MASLD predominant (69.00%), MetALD (18.77%), and ALD predominant (12.23%) groups. Temporal analysis revealed significant decreases in MASLD prevalence in the SLD population from 1999-2018 in general [average annual percentage change (AAPC) -4.802%, P=0.001], as well as in females, Mexican Americans, and Non-Hispanic Blacks. MetALD prevalence in the SLD population increased from 1999-2018 in general (AAPC +1.635%, P<0.001), and in males, females, Mexican Americans, Non-Hispanic Blacks and other ethnicities. No significant change in ALD prevalence was found. Compared to MASLD predominant individuals, ALD predominant individuals had higher risks of all-cause [hazard ratio (HR): 1.189, 95% confidence interval (CI): 1.026 to 1.378, P=0.02] and cancer-related mortality (subdistribution HR: 1.277, 95% CI: 1.032 to 1.579, P=0.02). No significant difference was observed for all-cause, cancer-related, or cardiovascular disease (CVD)-related mortality in MetALD and CVD-related mortality in ALD predominant individuals, relative to MASLD predominant individuals.
CONCLUSIONS: ALD predominant patients have higher all-cause and cancer-related mortality risks than MASLD predominant patients but not CVD-related mortality. SLD is highly heterogeneous in clinical characteristics, prevalence, and mortality risks which healthcare professionals must account for to avert adverse health outcomes.
METHODS: Data between 1999 to 2018 were extracted from National Health and Nutrition Examination Survey registries and analysed. Population baseline characteristics were evaluated across classifications of SLD. SLD was confirmed using either fatty liver index (FLI) or United States FLI (US-FLI). Multivariate analyses were used to study mortality-related outcomes.
RESULTS: The 20,510 individuals with SLD included were classified into MASLD predominant (69.00%), MetALD (18.77%), and ALD predominant (12.23%) groups. Temporal analysis revealed significant decreases in MASLD prevalence in the SLD population from 1999-2018 in general [average annual percentage change (AAPC) -4.802%, P=0.001], as well as in females, Mexican Americans, and Non-Hispanic Blacks. MetALD prevalence in the SLD population increased from 1999-2018 in general (AAPC +1.635%, P<0.001), and in males, females, Mexican Americans, Non-Hispanic Blacks and other ethnicities. No significant change in ALD prevalence was found. Compared to MASLD predominant individuals, ALD predominant individuals had higher risks of all-cause [hazard ratio (HR): 1.189, 95% confidence interval (CI): 1.026 to 1.378, P=0.02] and cancer-related mortality (subdistribution HR: 1.277, 95% CI: 1.032 to 1.579, P=0.02). No significant difference was observed for all-cause, cancer-related, or cardiovascular disease (CVD)-related mortality in MetALD and CVD-related mortality in ALD predominant individuals, relative to MASLD predominant individuals.
CONCLUSIONS: ALD predominant patients have higher all-cause and cancer-related mortality risks than MASLD predominant patients but not CVD-related mortality. SLD is highly heterogeneous in clinical characteristics, prevalence, and mortality risks which healthcare professionals must account for to avert adverse health outcomes.